search
Back to results

Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic

Primary Purpose

Acute Pain, Renal Colic

Status
Unknown status
Phase
Phase 3
Locations
Israel
Study Type
Interventional
Intervention
IV Ketamine
IM Ketamine
Sponsored by
Tel-Aviv Sourasky Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Acute Pain focused on measuring Morphine, Ketamine, Renal colic

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18-70
  • Self-report pain greater than or equal to 7/10 on a numerical-verbal scale
  • Weigh 50-100 kg
  • Have systolic blood pressure of 90-180 mmHg
  • Have an ASA (American Society of Anaesthesiologists' classification) score of 1-2

Exclusion Criteria:

  • Have had opioid analgesia administered within 6 hours of the study
  • Are chronic analgesia users (of opioid or others)
  • Have known allergies to morphine or ketamine
  • Are pregnant
  • Have a psychiatric history

Sites / Locations

  • Tel Aviv Sourasky Medical Center, department of Emergency Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

IV Ketamine

IM Ketamine

Arm Description

IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.

IM Ketamine group will receive IM Ketamine with IV morphine.

Outcomes

Primary Outcome Measures

Effectiveness of IM Ketamine in decreasing pain intensity [patient assessed - VAS pain score]
Time to achieve a clinically meaningful pain reduction was defined as the first time-point at which the patient reported 15mm of pain reduction or more. Maximal pain reduction was defined as the lowest VAS score reported by the patient over the course of follow-up. Time to maximal pain reduction was defined as the time at which the patient has the lowest VAS score over the course of the 1.5 hours follow-up.
Adverse effects [Opiate Related Symptom Distress Scale]
adverse effects [Opiate Related Symptom Distress Scale] [ Time Frame: 1.5 hour post administration ]

Secondary Outcome Measures

Full Information

First Posted
July 7, 2019
Last Updated
July 7, 2019
Sponsor
Tel-Aviv Sourasky Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04013958
Brief Title
Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic
Official Title
Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
August 1, 2019 (Anticipated)
Primary Completion Date
August 1, 2021 (Anticipated)
Study Completion Date
August 1, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Tel-Aviv Sourasky Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Patients who present to the emergency department (ED), with acute pain due to renal colic, are often treated with opioids. Treatment with opioids has many disadvantages - cardio-respiratory depression, nausea, vomiting and long term dependence. For these reasons, there is a constant search for a way to reduce the use of opioids. ketamine has been proven to augmented the analgesic effect of opioids, and thus reduce the use and adverse effects of opioids. Different studies about the use of Ketamine as a sedition agent have shown that Ketamine given IM versus IV has longer duration of effect with less adverse effects. The study we are conducting is designed to test and analyze the safety and efficacy of IV Ketamine with IV Morphine compared to IV Ketamine and morphine with IM placebo in a setting of acute pain due to, or suspected renal colic in the ED. When both ways of administration are given by the protocol as is customary for treatment of pain in the Emergency Medicine department, and will be a prospective, randomized, double blind, controlled study.
Detailed Description
The procedure: Eligible patients will be identified by the ED personnel. Research physician will address the patient, explain about the trial and ask the patient to sign a consent form. The patient will be randomized and assigned to a trial group: "A" or "B" and it will be noted in the Data sheet. According to physician order (IV amount and IM amount) and patient group assignment, the nurse will prepare and administer the different drugs. Patients in group "A" wiil receive IV Ketamine with IV morphine and IM placebo of normal saline. Patients in group "B" wiil receive IM Ketamine with IV morphine. The amount will be calculated based on the patients' weight: IV Morphine -0.1 mg/kg: Morphine vial contains 10 mg/10 ml. IV Ketamine -0.1 mg/kg: Ketamine vial contains 50 mg/1 ml. IM Ketamine -0.25 mg/kg: Ketamine vial contains 50 mg/1 ml. Prior to administering medication to the patient a research assistant, who is blinded to the choice of drugs given, will measure vital signs (blood pressure, heart rate and O2 saturation) as well as pain level on a 100 mm VAS (visual analogue scale) questionnaire. After administration of medications the researcher assistant will measure vital signs (blood pressure, heart rate and O2 saturation) as well as pain level on a 100 mm VAS questionnaire, at 5 and 10 minutes after administration, and then at 30, 45, 60, and 90 minutes. Measurement of vital signs will not interfere with any other treatment that the patients receives for their injury in the ED. Cardiorespiratory follow-up (as per bullet point number 8 above), will be concluded at 1.5 hours post-intervention, and clinical follow-up will continue as long as the patient remains in the ED. During the time of the the followup and after, if pain had not subsided sufficiently according to treating physician's clinical assessment, patient will receive further analgesic medications by physician order, as per ED protocol. The protocol takes into account concurrent medications.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Pain, Renal Colic
Keywords
Morphine, Ketamine, Renal colic

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Eligible patients will be randomized according to a blocked randomization scheme "WWW.RANDOMIZATION.COM" , which permits assignment of the participant to either group "A" or "group B" (the IM ketamine+IV morphine group or IV ketamine+IV morphine with IM saline (placebo) group. Eligible patients will be divided in equal proportions (50 in group A and 50 in group B).
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
IV Ketamine
Arm Type
Active Comparator
Arm Description
IV Ketamine group will receive IV Ketamine with IV morphine and IM saline.
Arm Title
IM Ketamine
Arm Type
Experimental
Arm Description
IM Ketamine group will receive IM Ketamine with IV morphine.
Intervention Type
Drug
Intervention Name(s)
IV Ketamine
Other Intervention Name(s)
No other
Intervention Description
IV Ketamine 0.1 mg/kg with IV morphine -0.1 mg/kg with IM Sailne 0.9%
Intervention Type
Drug
Intervention Name(s)
IM Ketamine
Intervention Description
IM Ketamine 0.3 mg/kg with IV morphine -0.1 mg/kg
Primary Outcome Measure Information:
Title
Effectiveness of IM Ketamine in decreasing pain intensity [patient assessed - VAS pain score]
Description
Time to achieve a clinically meaningful pain reduction was defined as the first time-point at which the patient reported 15mm of pain reduction or more. Maximal pain reduction was defined as the lowest VAS score reported by the patient over the course of follow-up. Time to maximal pain reduction was defined as the time at which the patient has the lowest VAS score over the course of the 1.5 hours follow-up.
Time Frame
1.5 hour post administration
Title
Adverse effects [Opiate Related Symptom Distress Scale]
Description
adverse effects [Opiate Related Symptom Distress Scale] [ Time Frame: 1.5 hour post administration ]
Time Frame
1.5 hour post administration

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18-70 Self-report pain greater than or equal to 7/10 on a numerical-verbal scale Weigh 50-100 kg Have systolic blood pressure of 90-180 mmHg Have an ASA (American Society of Anaesthesiologists' classification) score of 1-2 Exclusion Criteria: Have had opioid analgesia administered within 6 hours of the study Are chronic analgesia users (of opioid or others) Have known allergies to morphine or ketamine Are pregnant Have a psychiatric history
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Daniel Trotzky, MD
Phone
+97236973829
Email
danieltro@tlvmc.gov.il
First Name & Middle Initial & Last Name or Official Title & Degree
Omri Ritter, MD
Phone
+972508683149
Email
omrir@tlvmc.gov.il
Facility Information:
Facility Name
Tel Aviv Sourasky Medical Center, department of Emergency Medicine
City
Tel-Aviv
ZIP/Postal Code
6423906
Country
Israel

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
a table summering pain assessing questioners will be available from corresponding author on reasonable request.

Learn more about this trial

Comparison of Treatment by IM Ketamine to IV Ketamine in Patients With Renal Colic

We'll reach out to this number within 24 hrs